for sponsoring this event.
This event is sold out!
Bringing the typical drug to market today requires a $1B research and development commitment. How many companies can afford such a high barrier-to-entry without betting the company . . . or is the only way to bet the company?
Dr. Bernice Welles, formerly the VP Product Development at Genentech, is currently the VP Development at DiObex Inc., a start-up with drugs in development for diabetes. Bernice will talk about the $1B Barrier-to-Entry as well as other key issues that every savvy biotech executive, entrepreneur, and investor is thinking about.
When you think about it, the biotech industry really is a young industry--it has only been around for 35 years. Bernice is a veteran of the industry and has deep and broad experience in it. From her perspective as a senior executive in the business as well as from her perspective as a Venture Partner at MPM Capital, she will discuss the current start-up environment and where the industry is headed in the 21st century:
- How the biotech industry got started and current trends in the industry
- Today's challenges, including increased regulation, patent expiry, and waning productivity (as well as the $1B barrier-to-entry)
- What VCs and strategic buyers are looking at today in biotech
- The next hot growth opportunities in biotech
Register Online Date: Wednesday, February 13, 2008
Time: 6:00-6:30pm Networking Reception - light dinner. 6:30-7:45pm Talk and Q&A.
Location: Accenture LLP, 560 Mission Street, Suite 1200, San Francisco
Registration: WCNC Members, members of affiliate clubs, and their accompanied guests: $20 per person. Non-member alumni and other guests: $40 per person. If available, $10 additional for tickets purchased after 6:00pm, Monday, February 11. The WCNC's
standard cancellation policy applies for this event.
Dr. Bernice WellesDr. Welles was appointed Vice President, Development at DiObex in March 2005. Prior to that, she served as a Venture Partner at MPM Capital where she focused on evaluating potential investments with an emphasis on product candidates in discovery and development and worked closely with MPM’s portfolio companies to build their pipelines. Dr. Welles began her Biotechnology career at Genentech, Inc., where she ultimately served as Vice President of Product Development with responsibility for all development projects and portfolio planning. She was instrumental in the development and commercialization of a number of products, including Growth Hormone for Adult Growth Hormone Deficiency, Nutropin Depot, a long acting form of Genentech’s Growth Hormone, Raptiva for Psoriasis, and Lucentis, for Age-Related Macular Degeneration.
Dr. Welles is board certified in both Internal Medicine and in Endocrinology and Metabolism, having received an M.D. from Albany Medical College. She performed her residency training at Beth Israel Hospital in Boston and fellowship training at the University of California, San Francisco where she was the recipient of an NIH Clinical Investigator Development Award and where she stayed on as an Assistant Professor in the Department of Medicine prior to joining Genentech, Inc. Dr. Welles holds an M.S. in Urban and Environment Policy from Brandeis University and an MBA from the Wharton School at the University of Pennsylvania.
The WCNC would like to thank